On March 2, 2022 Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that the Company will participate in a virtual panel presentation at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 12:50 p.m. ET (Press release, Mersana Therapeutics, MAR 2, 2022, https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-present-cowen-42nd-annual-health-care [SID1234609362]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 30 days following the presentation.